I hereby conflit that this correspondence is being deposited with the United States Postal Service as first class mail in an ewolvey addressed to: Commissioner of Patents and Trademarks, Washington, O.C. 20231. on the Sate appearing below. Washington 8/25/88

ALL LIZLY AND COMPANY

Stration

PATENT

Group Art Unit: 123

Examiner: W. Davis

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Larry W. Hertel

Serial No.: 07/058,219

Filed : June 4, 1987

For : DIFLUORO ANTIVIRALS AND

INTERMEDIATE THEREFOR

Docket No.: X-5707B

INFORMATION DISCLOSURE STATEMENT III

Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

Applicant submits the enclosed patent document for the assistance of the Examiner in the consideration of the present case. Applicant regrets that the document was not supplied earlier; Applicant's attorney only became aware of it after the issuance of the present action, in the course of literature study concerning a different invention.

British Patent Application 2,125,401A shows nucleosides, said to be useful against Herpes diseases, which are desoxyuridine derivatives wherein the sugar moiety may have a single fluorine atom at the 2-position. The patent's compounds are therefore obviously distinct from the present nucleosides, which must have 2,2-difluoro substitution. It is also noticeable that the British application's base moieties have a saturated alkyl substituent on the ring, which is not permissible in any of the bases used in the present compounds.

U. S. Serial No. 07/058,219

Thus, the British application is not seen to be more important than the previously-cited articles and patents which show monofluoro compounds, but it is mentioned in order to complete the record and to assure that the Examiner is fully informed.

-2-

Respectfully submitted,

Joseph A. Jones Attorney for Applicant Registration No. 26,472

Phone: 317-276-5183

Eli Lilly and Company Patent Division/JAJ Lilly Corporate Center Indianapolis, Indiana 46285